Celularity (CELU) Current Deferred Revenue (2019 - 2025)
Celularity (CELU) posted quarterly Current Deferred Revenue of $8.1 million for Q4 2025, up 128.09% year-over-year from $3.5 million in Q4 2024, and down 3.52% quarter-over-quarter from $8.3 million in Q3 2025.
Celularity (CELU) Current Deferred Revenue (2019 - 2025) Analysis & Trends
Celularity (CELU) has reported Current Deferred Revenue for 7 consecutive years, with $8.1 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Current Deferred Revenue rose 128.09% year-over-year to $8.1 million; the TTM figure through Dec 2025 stood at $8.1 million (up 128.09% YoY), while the FY2025 annual figure was $8.1 million, up 128.09% from the prior year.
- Current Deferred Revenue retreated to $8.1 million in Q4 2025 per CELU's latest filing, from $8.3 million in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $11.9 million in Q1 2021 and bottomed at $2.8 million in Q2 2024.
- Historically, Current Deferred Revenue has averaged $5.6 million across 5 years, with a median of $4.5 million in 2022.
- Annual changes were most pronounced in 2021 — Current Deferred Revenue slumped 72.08% — and 2025, when it soared 128.09%.
- Celularity's Current Deferred Revenue stood at $4.1 million in 2021, then gained by 10.45% to $4.5 million in 2022, then surged by 34.02% to $6.0 million in 2023, then sank by 41.35% to $3.5 million in 2024, then soared by 128.09% to $8.1 million in 2025.
- Business Quant data shows CELU's Current Deferred Revenue at $8.1 million in Q4 2025, $8.3 million in Q3 2025, and $3.5 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.93 Bn | 131.08 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.11 Bn | 78.11 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.43 Bn | 60.25 Bn | 1.37 Bn |
| 4 | Moderna | 56.09 Bn | 50.96 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.13 Bn | 37.03 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.30 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.68 Bn | 9.29 Bn | 668.28 Mn |
| 8 | Insmed | 27.49 Bn | 26.32 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - |
| 10 | Celularity | 19.68 Mn | 13.50 Mn | -3.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 8.05 Mn |
| Sep 30, 2025 | 8.35 Mn |
| Jun 30, 2025 | 3.50 Mn |
| Mar 31, 2025 | 6.28 Mn |
| Dec 31, 2024 | 3.53 Mn |
| Sep 30, 2024 | 3.69 Mn |
| Jun 30, 2024 | 2.79 Mn |
| Mar 31, 2024 | 6.07 Mn |
| Dec 31, 2023 | 6.02 Mn |
| Sep 30, 2023 | 5.56 Mn |
| Jun 30, 2023 | 4.67 Mn |
| Mar 31, 2023 | 4.52 Mn |
| Dec 31, 2022 | 4.49 Mn |
| Sep 30, 2022 | 4.36 Mn |
| Jun 30, 2022 | 4.23 Mn |
| Mar 31, 2022 | 4.11 Mn |
| Dec 31, 2021 | 4.07 Mn |
| Sep 30, 2021 | 3.82 Mn |
| Jun 30, 2021 | 11.16 Mn |
| Mar 31, 2021 | 11.85 Mn |